

## Technology Appraisal Committee A Interests Register

**Topic: Inavolisib with palbociclib and fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-positive advanced breast cancer after adjuvant endocrine treatment [ID6425]**

**Publication Date: 12 June 2026**

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Becky Pennington	TAC Committee Member	Indirect - Financial	Becky has an ongoing methods research project with Pfizer on carers' HRQoL, paid to her employer UoS.	15/01/2026	It was agreed that Becky's declaration would not prevent her from participating in discussions on this appraisal.
Hugo Pedder	TAC Committee Member	Indirect – Financial	Hugo worked on a project for Roche on behalf of ConnectHEOR in Nov 2025, on an unrelated technology and indication - it was related to a diagnostic testing device.	10/02/2026	It was agreed that Hugo's declaration would not prevent him from participating in discussions on this appraisal.
Dr Mark Verrill	Clinical Expert	Direct – Financial	Dr Verrill receives intermittent ongoing payments from Roche for ad hoc advisory boards and speaker engagements. He has received travel sponsorship from Roche to attend medical congresses.	04/09/2025	It was agreed that Dr Verrill's declaration would not prevent him from providing expert advice to the committee.

<b>Name</b>	<b>Role with NICE</b>	<b>Type of interest</b>	<b>Description of interest</b>	<b>Interest declared</b>	<b>Comments</b>
		Indirect – Financial	Dr Verrill's department has received research funding from Roche for specific clinical trials		